Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade

Rhea-AI Filing Summary

Immuneering Corp's Chief Scientific Officer Brett Matthew Hall reported an open-market purchase of Class A Common Stock. On June 15, 2026, he bought 6,035 shares at a weighted average price of $4.15 per share. Following this transaction, he directly owns 382,531 shares of Immuneering Corp stock. The filing notes the trade was executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share, with the reported price representing the weighted average.

Insider Trade Summary

Net Buyer: 6,035 shares ($25,045)

Net Buy 1 txn

Insider Hall Brett Matthew

Role CHIEF SCIENTIFIC OFFICER

Bought 6,035 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	6,035	$4.15	$25K

Holdings After Transaction: Class A Common Stock — 382,531 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 6,035 shares Purchase price: $4.15 per share Post-transaction holdings: 382,531 shares +2 more

5 metrics

Shares purchased 6,035 shares Open-market purchase on June 15, 2026

Purchase price $4.15 per share Weighted average purchase price for acquired shares

Post-transaction holdings 382,531 shares Direct holdings after the June 15, 2026 transaction

Trade price range $4.146–$4.15 per share Range of execution prices across multiple trades

Net buy shares 6,035 shares Net change in position from this Form 4

Key Terms

open-market purchase, weighted average purchase price, broker-dealer, Form 4

4 terms

open-market purchase financial

"he bought 6,035 shares at a weighted average price in an open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The price reported in this column reflects the weighted average purchase price."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

broker-dealer financial

"This transaction was executed in multiple trades through a broker-dealer at prices ranging"

A broker-dealer is a licensed firm or individual that both executes trades on behalf of clients (acting as a broker) and buys or sells securities for its own account (acting as a dealer). Investors care because broker-dealers provide the plumbing of markets — they place orders, hold or move cash and securities, offer research or advice, and their stability and fees directly affect trade execution, costs, and the safety of client funds; think of them as a combined travel agent and taxi for your investments.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Brett Matthew

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/15/2026		P		6,035	A	$4.15(1)	382,531	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.146 to $4.15. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Brett Matthew Hall	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Immuneering Corp (IMRX) report on this Form 4?

Immuneering Corp reported that Chief Scientific Officer Brett Matthew Hall made an open-market purchase of Class A Common Stock. He acquired 6,035 shares on June 15, 2026 at a weighted average price of $4.15 per share, based on multiple broker-executed trades.

How many Immuneering Corp (IMRX) shares does Brett Matthew Hall hold after this transaction?

After the reported transaction, Chief Scientific Officer Brett Matthew Hall directly holds 382,531 shares of Immuneering Corp Class A Common Stock. This total reflects his position immediately following the June 15, 2026 open-market purchase of 6,035 shares at a weighted average price of $4.15.

At what prices did the Immuneering Corp (IMRX) insider trades occur on June 15, 2026?

The trades were executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share. The Form 4 reports a weighted average purchase price of $4.15 for the 6,035 shares of Immuneering Corp Class A Common Stock acquired that day.

Who is the insider involved in the latest Immuneering Corp (IMRX) Form 4 filing?

The insider is Brett Matthew Hall, Immuneering Corp’s Chief Scientific Officer. He reported an open-market purchase of 6,035 shares of Class A Common Stock on June 15, 2026, at a weighted average price of $4.15 per share, increasing his direct holdings to 382,531 shares.

Was the Immuneering Corp (IMRX) insider transaction an open-market purchase or another type?

The transaction was an open-market purchase of Class A Common Stock, coded as “P” on the Form 4. Brett Matthew Hall bought 6,035 shares at a weighted average price of $4.15, with trades executed through a broker-dealer across a small price range on June 15, 2026.